Table of Content

Table of Contents

Global Bullous Pemphigoid Therapies Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Bullous Pemphigoid Therapies Market by Value
2.2.1 Global Bullous Pemphigoid Therapies Revenue by Type
2.2.2 Global Bullous Pemphigoid Therapies Market by Value (%)
2.3 Global Bullous Pemphigoid Therapies Market by Production
2.3.1 Global Bullous Pemphigoid Therapies Production by Type
2.3.2 Global Bullous Pemphigoid Therapies Market by Production (%)

3. The Major Driver of Bullous Pemphigoid Therapies Industry
3.1 Historical & Forecast Global Bullous Pemphigoid Therapies Demand
3.2 Largest Application for Bullous Pemphigoid Therapies (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Bullous Pemphigoid Therapies Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Bullous Pemphigoid Therapies Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Bullous Pemphigoid Therapies Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Bullous Pemphigoid Therapies Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Bullous Pemphigoid Therapies Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Bullous Pemphigoid Therapies Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Bullous Pemphigoid Therapies Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Bullous Pemphigoid Therapies Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Bullous Pemphigoid Therapies Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Bullous Pemphigoid Therapies Average Price Trend
12.1 Market Price for Each Type of Bullous Pemphigoid Therapies in US (2018-2022)
12.2 Market Price for Each Type of Bullous Pemphigoid Therapies in Europe (2018-2022)
12.3 Market Price for Each Type of Bullous Pemphigoid Therapies in China (2018-2022)
12.4 Market Price for Each Type of Bullous Pemphigoid Therapies in Japan (2018-2022)
12.5 Market Price for Each Type of Bullous Pemphigoid Therapies in India (2018-2022)
12.6 Market Price for Each Type of Bullous Pemphigoid Therapies in Korea (2018-2022)
12.7 Market Price for Each Type of Bullous Pemphigoid Therapies in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Bullous Pemphigoid Therapies Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Bullous Pemphigoid Therapies

14. Bullous Pemphigoid Therapies Competitive Landscape
14.1 Regeneron Pharmaceuticals
14.1.1 Regeneron Pharmaceuticals Company Profiles
14.1.2 Regeneron Pharmaceuticals Product Introduction
14.1.3 Regeneron Pharmaceuticals Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Sanofi
14.2.1 Sanofi Company Profiles
14.2.2 Sanofi Product Introduction
14.2.3 Sanofi Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Pfizer
14.3.1 Pfizer Company Profiles
14.3.2 Pfizer Product Introduction
14.3.3 Pfizer Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 SUANFARMA
14.4.1 SUANFARMA Company Profiles
14.4.2 SUANFARMA Product Introduction
14.4.3 SUANFARMA Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Tecoland Corporation
14.5.1 Tecoland Corporation Company Profiles
14.5.2 Tecoland Corporation Product Introduction
14.5.3 Tecoland Corporation Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Century Pharmaceuticals
14.6.1 Century Pharmaceuticals Company Profiles
14.6.2 Century Pharmaceuticals Product Introduction
14.6.3 Century Pharmaceuticals Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Akari Therapeutics
14.7.1 Akari Therapeutics Company Profiles
14.7.2 Akari Therapeutics Product Introduction
14.7.3 Akari Therapeutics Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Immune Pharmaceuticals
14.8.1 Immune Pharmaceuticals Company Profiles
14.8.2 Immune Pharmaceuticals Product Introduction
14.8.3 Immune Pharmaceuticals Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Innate Pharma
14.9.1 Innate Pharma Company Profiles
14.9.2 Innate Pharma Product Introduction
14.9.3 Innate Pharma Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 AstraZeneca
14.10.1 AstraZeneca Company Profiles
14.10.2 AstraZeneca Product Introduction
14.10.3 AstraZeneca Bullous Pemphigoid Therapies Production, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Grifols
14.12 Aptalis
14.13 Medicis Pharmaceutical Corporation
14.14 Shaanxi Xiyue Pharmaceutical
14.15 Kunming Zhenhua Pharmaceutical Factory
14.16 Qinghai Pharmaceutical Factory
15. Conclusion
16. Methodology and Data Source

List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Bullous Pemphigoid Therapies Industry (Volume)
Figure 2. Bullous Pemphigoid Therapies Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Bullous Pemphigoid Therapies Revenue in 2022
Figure 5. US Bullous Pemphigoid Therapies Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Bullous Pemphigoid Therapies Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Bullous Pemphigoid Therapies Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Bullous Pemphigoid Therapies Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Bullous Pemphigoid Therapies Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Bullous Pemphigoid Therapies Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Bullous Pemphigoid Therapies Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Bullous Pemphigoid Therapies Revenue, by Type (Million USD) (2018-2028)
Table 4. Bullous Pemphigoid Therapies Production, by Type (K Unit) (2018-2028)
Table 5. Bullous Pemphigoid Therapies Demand (K Unit) by Application (2018-2028)
Table 6. Bullous Pemphigoid Therapies Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Bullous Pemphigoid Therapies Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Bullous Pemphigoid Therapies Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Bullous Pemphigoid Therapies Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Bullous Pemphigoid Therapies Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Bullous Pemphigoid Therapies Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Bullous Pemphigoid Therapies Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Bullous Pemphigoid Therapies Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Bullous Pemphigoid Therapies Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Bullous Pemphigoid Therapies in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Bullous Pemphigoid Therapies in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Bullous Pemphigoid Therapies in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Bullous Pemphigoid Therapies in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Bullous Pemphigoid Therapies in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Bullous Pemphigoid Therapies in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Bullous Pemphigoid Therapies in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Regeneron Pharmaceuticals Profiles
Table 61. Regeneron Pharmaceuticals Bullous Pemphigoid Therapies Product Introduction
Table 62. Regeneron Pharmaceuticals Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Regeneron Pharmaceuticals Strategic initiatives
Table 64. Sanofi Profiles
Table 65. Sanofi Bullous Pemphigoid Therapies Product Introduction
Table 66. Sanofi Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Sanofi Strategic initiatives
Table 68. Pfizer Profiles
Table 69. Pfizer Bullous Pemphigoid Therapies Product Introduction
Table 70. Pfizer Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Pfizer Strategic initiatives
Table 72. SUANFARMA Profiles
Table 73. SUANFARMA Bullous Pemphigoid Therapies Product Introduction
Table 74. SUANFARMA Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. SUANFARMA Strategic initiatives
Table 76. Tecoland Corporation Profiles
Table 77. Tecoland Corporation Bullous Pemphigoid Therapies Product Introduction
Table 78. Tecoland Corporation Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Tecoland Corporation Strategic initiatives
Table 80. Century Pharmaceuticals Profiles
Table 81. Century Pharmaceuticals Bullous Pemphigoid Therapies Product Introduction
Table 82. Century Pharmaceuticals Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. Century Pharmaceuticals Strategic initiatives
Table 84. Akari Therapeutics Profiles
Table 85. Akari Therapeutics Bullous Pemphigoid Therapies Product Introduction
Table 86. Akari Therapeutics Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. Akari Therapeutics Strategic initiatives
Table 88. Immune Pharmaceuticals Profiles
Table 89. Immune Pharmaceuticals Bullous Pemphigoid Therapies Product Introduction
Table 90. Immune Pharmaceuticals Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. Immune Pharmaceuticals Strategic initiatives
Table 92. Innate Pharma Profiles
Table 93. Innate Pharma Bullous Pemphigoid Therapies Product Introduction
Table 94. Innate Pharma Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. Innate Pharma Strategic initiatives
Table 97. AstraZeneca Profiles
Table 98. AstraZeneca Bullous Pemphigoid Therapies Product Introduction
Table 99. AstraZeneca Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 100. AstraZeneca Strategic initiatives
Table 101. Grifols Profiles
Table 102. Grifols Bullous Pemphigoid Therapies Product Introduction
Table 103. Grifols Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 104. Grifols Strategic initiatives
Table 105. Aptalis Profiles
Table 106. Aptalis Bullous Pemphigoid Therapies Product Introduction
Table 107. Aptalis Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 108. Aptalis Strategic initiatives
Table 109. Medicis Pharmaceutical Corporation Profiles
Table 110. Medicis Pharmaceutical Corporation Bullous Pemphigoid Therapies Product Introduction
Table 111. Medicis Pharmaceutical Corporation Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 112. Medicis Pharmaceutical Corporation Strategic initiatives
Table 113. Shaanxi Xiyue Pharmaceutical Profiles
Table 114. Shaanxi Xiyue Pharmaceutical Bullous Pemphigoid Therapies Product Introduction
Table 115. Shaanxi Xiyue Pharmaceutical Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 116. Shaanxi Xiyue Pharmaceutical Strategic initiatives
Table 117. Kunming Zhenhua Pharmaceutical Factory Profiles
Table 118. Kunming Zhenhua Pharmaceutical Factory Bullous Pemphigoid Therapies Product Introduction
Table 119. Kunming Zhenhua Pharmaceutical Factory Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 120. Kunming Zhenhua Pharmaceutical Factory Strategic initiatives
Table 121. Qinghai Pharmaceutical Factory Profiles
Table 122. Qinghai Pharmaceutical Factory Bullous Pemphigoid Therapies Product Introduction
Table 123. Qinghai Pharmaceutical Factory Bullous Pemphigoid Therapies Production (Unit), Revenue (Million USD) (2018-2022)
Table 124. Qinghai Pharmaceutical Factory Strategic initiatives